GSK plc Sponsored ADR (GS70)
Summary
GS70 Chart
Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences
President Donald Trump's latest executive order calls for splitting the measles, mumps and rubella, or MMR, vaccine into three separate shots. But doctors and other experts say that effort has no scientific basis and is unlikely to get off the ground.
GSK Beats Q2 Earnings & Revenue Estimates, Announces Cost-Saving Plan
GSK beats Q2 earnings and revenue estimates, reaffirms 2026 guidance and unveils a new cost-saving plan.
GSK Q2 Earnings Call Highlights
GSK NYSE: GSK reported second-quarter sales growth of 5% at constant exchange rates to more than £8.4 billion, supported by Specialty Medicines and Vaccines, while outlining a new cost-savings and investment program intended to accelerate its late-stage pipeline and support growth beyond 2031.
GSK plc Sponsored ADR (GS70) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has GSK plc Sponsored ADR ever had a stock split?
GSK plc Sponsored ADR Profile
| Pharmaceuticals Industry | Healthcare Sector | Luke Victor Miels CEO | XFRA Exchange | 37733W204 CUSIP |
| GB Country | 66,841 Employees | 14 Aug 2026 Last Dividend | 22 Jul 2022 Last Split | - IPO Date |
Overview
GSK plc, previously known as GlaxoSmithKline plc until its name change in May 2022, stands as a formidable entity in the pharmaceutical sector with a rich history dating back to 1715. With its global headquarters in Brentford, the United Kingdom, GSK focuses on the research, development, and manufacturing of pharmaceuticals, including vaccines and specialty medicines aimed at preventing and treating a myriad of diseases. This multinational corporation has a broad operational footprint spanning the United Kingdom, the United States, and other international markets. GSK is structured into two main operational segments: Commercial Operations and Total R&D (Research & Development), indicating a robust commitment to innovation in healthcare. Additionally, GSK plc actively engages in strategic collaborations, such as those with CureVac for mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for the advancement of oligonucleotide platform technologies.
Products and Services
GSK's portfolio encompasses a wide range of vaccines and medications designed to combat various diseases, underpinned by the company's significant investments in research and development:
- Vaccines: GSK’s vaccine division offers preventive solutions for shingles, meningitis, respiratory syncytial virus (RSV), flu, polio, and influenza. The company also addresses global healthcare needs by developing vaccines for pandemics, illustrating its commitment to public health and safety.
- HIV Medicines: GSK plc is a key player in the fight against HIV/AIDS, providing innovative medicines that are essential in the management of this chronic condition, thereby improving the quality of life for those affected.
- Oncology: The company’s oncology portfolio consists of treatments for various cancers, underscoring GSK's role in advancing cancer care through research and development of new, potentially life-saving therapies.
- Respiratory/Immunology: GSK offers inhaled medications for asthma and chronic obstructive pulmonary disease (COPD), in addition to medicines for other respiratory and immunological conditions. These products reflect the company’s dedication to enhancing respiratory health and immune system management.
- Antibiotics: Recognizing the importance of combating infectious diseases, GSK also manufactures antibiotics to treat a range of infections, contributing to the global fight against antibiotic resistance and infectious threats.
- Collaborative Agreements: Beyond its in-house product line, GSK engages in strategic collaborations to develop next-generation vaccines and therapies, such as mRNA-based influenza vaccines in partnership with CureVac, and advancements in oligonucleotide platform technologies with Wave Life Sciences and Elsie Biotechnologies, Inc. These partnerships are vital to GSK’s strategy of leveraging external expertise and technology to enhance its R&D pipeline.
